


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-9 (Cancelled).

10. (New) A method for preventing/ameliorating diabetic maculopathy in a mammal comprising administering to the subject an effective amount of a compound represented by the following general formula:



wherein X represents a halogen or a hydrogen atom, R<sup>1</sup> and R<sup>2</sup> concurrently or differently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R<sup>1</sup> and R<sup>2</sup>, together with a nitrogen atom bound thereto and optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle.


11. (New) The method for preventing/ameliorating diabetic maculopathy according to claim 10, wherein the compound is administered in the form of an oral agent.

12. (New) The method for preventing/ameliorating diabetic maculopathy according to claim 10, wherein the compound is (2S, 4S)-6-fluoro-2',5'-dioxospiro [chroman-4,4'-imidazolidine]-2-carboxamide.

13. (New) The method for preventing/ameliorating diabetic maculopathy according to claim 10, which is used for treating macular edema or retinal pigment epitheliopathy in diabetic maculopathy.

14. (New) The method for preventing/ameliorating diabetic maculopathy according to claim 10, which is used for improving visual acuity or inhibiting a deterioration of visual acuity in diabetic maculopathy.

15. (New) A method for improving visual acuity or inhibiting a deterioration of visual acuity in diabetic maculopathy in a mammal comprising administering to the subject an effective amount of a compound represented by the following general formula:



wherein  $X$  represents a halogen or a hydrogen atom,  $R^1$  and  $R^2$  concurrently or differently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or  $R^1$  and  $R^2$ , together with a nitrogen atom bound thereto and optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle.

16. (New) The method for improving visual acuity or inhibiting a deterioration of visual acuity in diabetic maculopathy according to claim 15, wherein the compound is administered in the form of an oral agent.

17. (New) The method for improving visual acuity or inhibiting a deterioration of visual acuity in diabetic maculopathy according to claim 15, wherein the compound is (2S, 4S)-6-fluoro-2',5'-dioxospiro [chroman-4,4'-imidazolidine]-2-carboxamide.